|
|
|
| Clinical Study on Bevacizumab Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Rectal Cancer |
| HU Chun-xia, JIANG Wei-mei, LI Xiao-min,et al |
| Department of Oncology,Lianyungang Second People's Hospital,Lianyungang,Jiangsu,222006 |
|
|
|
|
Abstract 【Objective】To observe the clinical effect of bevacizumab combined with 5-fluorouracil (5-Fu), leucovorin (LV) and oxaliplatin (L-OHP) (FOLFOX4) chemotherapy regimen in the treatment of advanced rectal cancer. 【Methods】Eighty-six patients with advanced rectal cancer who were admitted to our hospital were selected as study subjects. According to order of hospitalization, the subjects were numbered and were randomized into a control group and an observation group, with 43 cases in each group. Both groups received FOLFOX4 first-line chemotherapy. The observation group was treated with bevacizumab in addition to this. The treatment effects,toxicity and survival rate were compared between the two groups. Both groups were followed up for 2 years. The survival rate was recorded and the quality of life was evaluated by European organization for research and treatment of cancer quality of life questionnaire (EORTC QLC-CR37 ). 【Results】① The total response rate in the observation group was higher than that in the control group (P<0.05). ② There was no significant difference in the incidence of toxic and side effects between the two groups (P>0.05). ③ After 2 years of follow-up, the overall survival rate of the observation group was higher than that of the control group (P<0.05). ④ After 3, 6, 12 and 24 months of treatment, the quality of life scores of both groups decreased (P<0.05), and the decrease in the observation group was greater than that in the control group (P<0.05). 【Conclusion】The application of bevacizumab combined with FOLFOX4 chemotherapy in treatment of advanced rectal cancer has a high total response rate, can improve the 2-year survival rate of patients and can optimize the quality of life.
|
|
Received: 28 July 2016
|
|
|
|
|
|
[1] 周彤, 徐建忠, 李苏宜,等.恩度联合FOLFOX4方案治疗晚期结肠癌、直肠癌的多中心临床研究[J].实用临床医药杂志, 2012, 16(5):26-28.
[2] 贺佳蓓, 屈景辉. 固本解毒法联合FOLFOX4方案化疗治疗晚期或复发性直肠癌的临床研究[J].四川中医, 2013,31(12):76-78.
[3] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[4] 抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J].癌症,1992,03:254.
[5] 姜宝法,刘春晓,崔永春,等.EORTC QLQ-C30的信度、效度研究[J].中国临床心理学杂志,2005,13(1):31-32,36.
[6] 谢永铮, 任学群. 贝伐珠单抗联合FOLFOX治疗晚期转移性结直肠癌的临床疗效及安全性评价[J].中国临床药理学杂志, 2015, 31(22):2208-2210.
[7] 时淑珍, 于韦韦, 张捷,等.贝伐珠单抗联合FOLFIRI方案一线治疗转移性结直肠癌的临床研究[J].癌症进展, 2013, 11(05):461-464.
[8] 晏建华,邓亨怡,黄雄.局部复发直肠癌的诊治现状与展望[J].西部医学, 2016, 28(2):292-296.
[9] 焦婉, 肖菊香, 锁爱莉,等.贝伐珠单抗联合化疗治疗晚期结直肠癌的疗效观察[J].西安交通大学学报(医学版), 2016, 37(1):108-112.
[10] 何干, 杨强, 李启刚,等.西妥昔单抗或贝伐单抗联合FOLFOX4方案治疗晚期直肠癌患者的临床观察[J].中国药房, 2016,27(8):1078-1081.
[11] 韩志军.贝伐单抗联合FOLFOX4方案治疗晚期结直肠癌的临床疗效观察[J].结直肠肛门外科, 2015,21(1):35-38.
[12] 汪楠, 袁苏徐, 胡文杰,等.贝伐单抗联合FOLFOX4方案治疗12例初治失败转移性结直肠癌的临床观察[J].实用癌症杂志, 2012, 27(4):376-378. |
|
|
|
2016, Vol. 33 
